133 related articles for article (PubMed ID: 16030295)
1. New checkpoint blockers begin human trials.
Garber K
J Natl Cancer Inst; 2005 Jul; 97(14):1026-8. PubMed ID: 16030295
[No Abstract] [Full Text] [Related]
2. New drugs target hypoxia response in tumors.
Garber K
J Natl Cancer Inst; 2005 Aug; 97(15):1112-4. PubMed ID: 16077066
[No Abstract] [Full Text] [Related]
3. Epothilone D (Kosan/Roche).
Kolman A
Curr Opin Investig Drugs; 2004 Jun; 5(6):657-67. PubMed ID: 15242255
[TBL] [Abstract][Full Text] [Related]
4. OSI-461 (OSI).
Galmarini CM
Curr Opin Investig Drugs; 2004 Jun; 5(6):648-56. PubMed ID: 15242254
[TBL] [Abstract][Full Text] [Related]
5. [In vitro inhibitory effect of dibenzoxanthene CY-B12 on proliferation of tumor cell lines and its possible mechanisms].
Pu XX; Jiang GF; Chen Y; Xu ZL; Xian LJ
Ai Zheng; 2005 Dec; 24(12):1442-7. PubMed ID: 16351789
[TBL] [Abstract][Full Text] [Related]
6. DNA structure and integrity checkpoints during the cell cycle and their role in drug targeting and sensitivity of tumor cells to anticancer treatment.
Skladanowski A; Bozko P; Sabisz M
Chem Rev; 2009 Jul; 109(7):2951-73. PubMed ID: 19522503
[No Abstract] [Full Text] [Related]
7. Slow start to phase 0 as researchers debate value.
Twombly R
J Natl Cancer Inst; 2006 Jun; 98(12):804-6. PubMed ID: 16788150
[No Abstract] [Full Text] [Related]
8. Diflomotecan. Ipsen.
Osheroff N
IDrugs; 2004 Mar; 7(3):257-63. PubMed ID: 15011101
[No Abstract] [Full Text] [Related]
9. [Induction of G2 /M phase arrest and apoptosis of MCF-7 cells by novel benzofuran lignan via suppressing cell cycle proteins].
Yang H; Cai YC; Pang JY; Li YQ; Zeng ZL; Xu ZL; Xian LJ
Yao Xue Xue Bao; 2008 Feb; 43(2):138-44. PubMed ID: 18507339
[TBL] [Abstract][Full Text] [Related]
10. AE-941 (AEterna).
Dredge K
Curr Opin Investig Drugs; 2004 Jun; 5(6):668-77. PubMed ID: 15242256
[TBL] [Abstract][Full Text] [Related]
11. BRCA1 contributes to cell cycle arrest and chemoresistance in response to the anticancer agent irofulven.
Wiltshire T; Senft J; Wang Y; Konat GW; Wenger SL; Reed E; Wang W
Mol Pharmacol; 2007 Apr; 71(4):1051-60. PubMed ID: 17229870
[TBL] [Abstract][Full Text] [Related]
12. MS-209 Schering.
Robert J
Curr Opin Investig Drugs; 2004 Dec; 5(12):1340-7. PubMed ID: 15648956
[TBL] [Abstract][Full Text] [Related]
13. TG-4010 Transgene.
Cohen S; Kaufman HL
Curr Opin Investig Drugs; 2004 Dec; 5(12):1319-28. PubMed ID: 15648954
[TBL] [Abstract][Full Text] [Related]
14. AN-9 (Titan).
Hobdy E; Murren J
Curr Opin Investig Drugs; 2004 Jun; 5(6):628-34. PubMed ID: 15242252
[TBL] [Abstract][Full Text] [Related]
15. Activation of both Mos and Cdc25 is required for G2-M transition in perch oocyte.
Priyadarshini A; Basu D; Navneet AK; Bhattacharya A; Bhattacharya S; Maitra S; Bhattacharya S
Mol Reprod Dev; 2009 Mar; 76(3):289-300. PubMed ID: 18671273
[TBL] [Abstract][Full Text] [Related]
16. G1 arrest induction represents a critical determinant for cisplatin cytotoxicity in G1 checkpoint-retaining human cancers.
Un F
Anticancer Drugs; 2007 Apr; 18(4):411-7. PubMed ID: 17351393
[TBL] [Abstract][Full Text] [Related]
17. Clinical trials of novel and targeted therapies: endpoints, trial design, and analysis.
Suman VJ; Dueck A; Sargent DJ
Cancer Invest; 2008 Jun; 26(5):439-44. PubMed ID: 18568764
[No Abstract] [Full Text] [Related]
18. Inhibition of the G2 DNA damage checkpoint by oliveroline isolated from Duguetia odorata.
Brastianos HC; Sturgeon CM; Roberge M; Andersen RJ
J Nat Prod; 2007 Feb; 70(2):287-8. PubMed ID: 17315964
[TBL] [Abstract][Full Text] [Related]
19. 27th Annual JPMorgan Healthcare Conference--BioCryst and Emergent Biosolutions.
Croasdell G; Gale S
IDrugs; 2009 Mar; 12(3):149-51. PubMed ID: 19333891
[No Abstract] [Full Text] [Related]
20. Cancer drugs. Weighing the risks and benefits.
Bren L
FDA Consum; 2007; 41(1):10-9. PubMed ID: 17342832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
